Targeting proteins to fight acute myeloid leukaemia
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Can radiotherapy near the spleen lead to severe infections later in life?
Looking into whether survivors of childhood cancer are at risk of severe infections.
Paediatric Hepatic International Tumour Trial
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
New treatments for relapsed rhabdomyosarcoma
Developing better models of rhabdomyosarcoma to test available treatments.
Investigating how regulatory regions of the genome communicate with cancer causing genes
Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene
Developing less toxic therapies for children with acute lymphoblastic leukaemia
Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.
Developing innovative models to support research for kinder treatments for B cell lymphoma
Glo-BNHL trial is an international trial that will recruit children across the globe with relapse BNHL and assign them to the trial to receive a novel therapy. We are requesting funds to conduct biological studies alongside the trial to improve our understanding of this cancer.
Designing better treatments for paediatric ependymoma
Immunotherapy could be a potential treatment for ependymoma. To make immunotherapy effective we need to know more about how ependymoma works.